July 30, 2019 – Procyrion Inc. secured Breakthrough Device designation by the U.S. Food and Drug Administration (FDA...
Heart Failure
This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congesitive heart failure (CHF). The channel includes news on HFpEF and HFrEF.
News | Cardiovascular Clinical Studies | July 03, 2019
July 3, 2019 — The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to...
Videos | Heart Failure | June 28, 2019
Image courtesy of Kapur N.K., Karas R.H., Burkhoff D., et al.
News | Heart Failure | June 17, 2019
June 17, 2019 – Results from a first-in-man proof of concept study found occlusion of the superior vena cava (SVC)...
News | Pharmaceuticals | June 14, 2019
June 14, 2019 — Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its...
News | Ventricular Assist Devices (VAD) | June 12, 2019
June 12, 2019 — In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that...
News | Heart Valve Technology | May 22, 2019
May 22, 2019 — Edwards Lifesciences Corp. announced strategic clinical and regulatory milestones for its Edwards...
News | Cardiac Resynchronization Therapy Devices (CRT) | May 15, 2019 | Dave Fornell, Editor
May 15, 2019 — A pilot trial has shown His pacing in...
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
May 14, 2019 — The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and...
Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM.
Technology | Heart Failure | May 06, 2019
May 6, 2019 — The U.S. Food and Drug Administration (FDA) approved tafamidis meglumine (Vyndaqel) and tafamidis (...
The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.
Feature | Heart Failure | April 29, 2019 | Will Clifton, M.D.
The heart and kidneys are inextricably linked through a diverse web of hemodynamic, neural and hormonal mechanisms....
News | Heart Failure | April 19, 2019
April 19, 2019 – Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently...
News | Heart Failure | March 29, 2019
March 29, 2019 — The cardiovascular benefits of the diabetes...
![New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entresto) continued to deliver reductions in the heart failure biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP), an established biomarker for heart failure severity and prognosis.[1] The data was presented as a late-breaker at the American College of Cardiology (ACC) 2019 Annual Scientific Session in March.](https://www.dicardiology.com/sites/daic/files/styles/content_feed_medium/public/Entresto_bottles.jpg?itok=zkKfDjIR)
News | Heart Failure | March 27, 2019
March 27, 2019 —New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/...
